6990 — Sichuan Kelun-Biotech Biopharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$108.71bn
- HK$103.19bn
- CNY2.06bn
Brief: Sichuan Kelun-Biotech Biopharmaceutical Says Investigational New Drug Approval For SKB571 By NMPA
Brief: Sichuan Kelun-Biotech Biopharmaceutical Updates On Sacituzumab Tirumotecan
Brief: Sichuan Kelun-Biotech Biopharmaceutical Says Subscription For Structured Deposit
Brief: Sichuan Kelun-Biotech Biopharmaceutical To Subscribe For Structured Deposit
Brief: Sichuan Kelun-Biotech Biopharmaceutical Says Drug Application For Sacituzumab Tirumotecan Accepted By NMPA
Brief: Sichuan Kelun-Biotech Biopharmaceutical Posts HY Profit RMB310.2 Million
Brief: Sichuan Kelun-Biotech Biopharmaceutical Announces Subscription Of Structured Deposits
Brief: Sichuan Kelun-Biotech Biopharmaceutical Says Subscription For Structured Deposit
Brief: Sichuan Kelun-Biotech Biopharmaceutical Announces Purchase Of Equipment
Brief: Sichuan Kelun-Biotech Biopharmaceutical Subscribes For Structured Deposit Products
Sichuan Kelun-Biotech jumps on approval for investigational new drug
Brief: Sichuan Kelun-Biotech Biopharmaceutical Says Investigational New Drug Approval For Innovative Drug- Skb518 For Injection By Nmpa
Brief: Sichuan Kelun-Biotech Biopharmaceutical Says Wang Jingyi Resigned As An Executive Director
Brief: Sichuan Kelun-Biotech Biopharmaceutical Says Placing Of New Shares
Kelun-Biotech jumps on progress of key product development
Brief: Sichuan Kelun-Biotech Biopharmaceutical Says Key Product A400 (Ep0031) Cleared To Start Phase 2 By US FDA
Brief: Sichuan Kelun-Biotech Biopharmaceutical Announces Subscription For Structured Deposits
Brief: Sichuan Kelun-Biotech Biopharmaceutical Posts FY Loss RMB574.1 Million
Sichuan Kelun-Biotech jumps on progress of core product's development